Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenia-like psychosis after traumatic brain injury [6]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 505-507

  Bennouna, Mehdi ^a   Greene, Valerie B ^b   Defranoux, Luc ^a  

^a Centre Hospitalier Spécialisé de Sarreguemines   (France)

^b Centre Hospitalier Specialisé de Brumath   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; GALANTAMINE; RISPERIDONE; ZOPICLONE;

ADULT; BRAIN INJURY; CASE REPORT; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LETTER; MEMORY DISORDER; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN HEMORRHAGE, TRAUMATIC; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; GALANTAMINE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIC PSYCHOLOGY;

EID: 25444509616     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177851.31157.66     Document Type: Letter

References (16)

1. Arciniegas DB. The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Curr Psychiatry Rep. October 2003;5(5):391-399.
2. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology. June 2004;174(1):45-53.
3. McAllister TW, Ferrell RB. Evaluation and treatment of psychosis after traumatic brain injury. Neurol Rehabil. 2002;17(4):357-368.
4. Zhang Q, Sachdev PS. Psychotic disorder and traumatic brain injury. Curr Psychiatry Rep. July 2003;5(3):197-201.
5. Davison K, Bagley CR. Schizophrenia-like psychosis associated with organic disorders of the central nervous system. Br J Psychiatry. 1969;114:113-184.
6. Silver J, Yudofsky SC, Hales RE. Neuropsychiatry of Traumatic Brain Injury. Washington, DC: American Psychiatric Press; 1994:189-218.
7. Sachdev P, Smith JS, Cathcart S. Schizophrenia-like psychosis following traumatic brain injury: a chart-based descriptive and case-control study. Psychol Med. February 2001;31(2):231-239.
8. Fujii D, Ahmed I. Characteristics of psychotic disorder due to traumatic brain injury an analysis of case studies in the literature. J Neuropsychiatry Clin Neurosci. Spring 2002;14(2):130-140.
9. Hazlett EA, Buchsbaum MS, Jeu LA, et al. Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr Res. May 25, 2000;43(1):33-46.
10. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. October 1995;52(10):805-818. [discussion 819-820].
11. Ichikawa J, Dai J, O'Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. March 2002;26(3):325-339.
12. Schreiber S, Klag E, Gross Y, et al. Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. Int Clin Psychopharmacol. 1998;13:273-275.
13. Chen Y, Shohami E, Constantini S, et al. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. J Neurotrauma. April 1998;15(4);231-237.
14. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol. September-October 2002;25(5):272-275.
15. Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry. July 2002;159(7):1244-1245.
16. Allen TB, McEvoy JP, Keefe R, et al. Galantamine as an adjunctive therapy in the treatment of schizophrenia. Presented at: 11th Congress of the International Psychogeriatric Association (IPA); Aug 17-22, 2003; Chicago, Ill.